Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Scheffer, I. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scheffer, I. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 126, No. 3, 513-514, March 2003
© 2003 Guarantors of Brain
doi: 10.1093/brain/awg047

Editorial

Severe infantile epilepsies: molecular genetics challenge clinical classification

Ingrid E. Scheffer1

1 University of Melbourne, Austin and Repatriation Medical Centre, Royal Children’s Hospital and Monash Medical Centre, Melbourne, Australia

The first 10% of the full text of this article appears below.

In 1978, Charlotte Dravet described the ‘cryptogenic’ epilepsy syndrome severe myoclonic epilepsy of infancy (SMEI) (Dravet, 1978Go). This severe generalized epileptic encephalopathy begins at around 6 months of age with febrile hemiclonic or generalized status epilepticus. Hemiclonic status typically recurs involving each side independently. After 1 year of age, other seizure types appear including absence, partial, atonic and often myoclonic seizures. Early development is normal, with slowing and regression after 1 to 2 years; pyramidal features and ataxia may also evolve. The prognosis is poor. The recent draft proposal of the ILAE classification suggests the eponymous name Dravet syndrome instead of SMEI . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BrainHome page
L. A. Harkin, J. M. McMahon, X. Iona, L. Dibbens, J. T. Pelekanos, S. M. Zuberi, L. G. Sadleir, E. Andermann, D. Gill, K. Farrell, et al.
The spectrum of SCN1A-related infantile epileptic encephalopathies
Brain, March 1, 2007; 130(3): 843 - 852.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. C. Mulley, P. Nelson, S. Guerrero, L. Dibbens, X. Iona, J. M. McMahon, L. Harkin, J. Schouten, S. Yu, S. F. Berkovic, et al.
A new molecular mechanism for severe myoclonic epilepsy of infancy: Exonic deletions in SCN1A.
Neurology, September 26, 2006; 67(6): 1094 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. Borgatti, C. Zucca, A. Cavallini, M. Ferrario, C. Panzeri, P. Castaldo, M. V. Soldovieri, C. Baschirotto, N. Bresolin, B. D. Bernardina, et al.
A novel mutation in KCNQ2 associated with BFNC, drug resistant epilepsy, and mental retardation
Neurology, July 13, 2004; 63(1): 57 - 65.
[Abstract] [Full Text] [PDF]